亚宝药业：SY-5项目新适应症获临床试验批准通知书

Core Viewpoint - The announcement indicates that the company’s subsidiary, Suzhou Yabao Pharmaceutical Research Co., Ltd., has received approval from the National Medical Products Administration for a new indication for the SY-005 injection, specifically for clinical trials targeting neurological deficits after brain glioma surgery [1] Group 1 - The approval notification number for the clinical trial is 2025LP02198 [1] - The new indication for SY-005 injection is for neurological deficits following brain glioma surgery, which is currently in the Phase II clinical trial stage [1]